Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Feeney

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Dermatology and Therapy|June 19, 2024
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic DermatitisApril W Armstrong, Andrew F Alexis, Andrew Blauvelt, et al.
Neurorehabilitation|June 10, 2019
Cognitive impairment and health-related quality of life following traumatic brain injuryNikos Gorgoraptis, Joanna Zaw-Linn, Claire Feeney, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 31, 2022
Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysisJashin J Wu, Chih-Ho Hong, Joseph F Merola, et al.
The Journal of Dermatological Treatment|April 10, 2023
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trialCarsten Flohr, Michael J Cork, Michael R Ardern-Jones, et al.
International Archives of Allergy and Immunology|February 23, 2026
Efficacy of Abrocitinib and Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Using Treat-to-Target Goals Recommended by Experts in ChinaZuotao Zhao, Xing-Hua Gao, Yangfeng Ding, et al.
Clinical Endocrinology|May 20, 2025
Radiological Activity Score (RAS)-MRI Characteristics in Dysthyroid Optic Neuropathy in a Multi-Ethnic Thyroid Eye Disease PopulationMalik Moledina, Vickie Lee, Kunwar Bhatia, et al.
Advances in Therapy|July 13, 2022
Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database AnalysisJashin J Wu, Marie-Hélène Lafeuille, Bruno Emond, et al.
JAMA Dermatology|June 4, 2020
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialJonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, et al.
American Journal of Clinical Dermatology|May 6, 2021
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported OutcomesJonathan I Silverberg, Jacob P Thyssen, Eric L Simpson, et al.
Dermatology and Therapy|July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety ConsiderationsMelinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Dermatology and Therapy|June 19, 2024
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic DermatitisApril W Armstrong, Andrew F Alexis, Andrew Blauvelt, et al.
Neurorehabilitation|June 10, 2019
Cognitive impairment and health-related quality of life following traumatic brain injuryNikos Gorgoraptis, Joanna Zaw-Linn, Claire Feeney, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 31, 2022
Predictors of nonresponse to dupilumab in patients with atopic dermatitis: A machine learning analysisJashin J Wu, Chih-Ho Hong, Joseph F Merola, et al.
The Journal of Dermatological Treatment|April 10, 2023
Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trialCarsten Flohr, Michael J Cork, Michael R Ardern-Jones, et al.
International Archives of Allergy and Immunology|February 23, 2026
Efficacy of Abrocitinib and Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Using Treat-to-Target Goals Recommended by Experts in ChinaZuotao Zhao, Xing-Hua Gao, Yangfeng Ding, et al.
Clinical Endocrinology|May 20, 2025
Radiological Activity Score (RAS)-MRI Characteristics in Dysthyroid Optic Neuropathy in a Multi-Ethnic Thyroid Eye Disease PopulationMalik Moledina, Vickie Lee, Kunwar Bhatia, et al.
Advances in Therapy|July 13, 2022
Real-World Effectiveness of Newly Initiated Systemic Therapy for Atopic Dermatitis in the United States: A Claims Database AnalysisJashin J Wu, Marie-Hélène Lafeuille, Bruno Emond, et al.
JAMA Dermatology|June 4, 2020
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical TrialJonathan I Silverberg, Eric L Simpson, Jacob P Thyssen, et al.
American Journal of Clinical Dermatology|May 6, 2021
Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported OutcomesJonathan I Silverberg, Jacob P Thyssen, Eric L Simpson, et al.
Dermatology and Therapy|July 2, 2024
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety ConsiderationsMelinda J Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, et al.
Pageof 4